Malar's Bet on Attaboy Labs Signals a Shift in Wellness

TORONTO – April 29, 2026 – In a move that underscores a significant shift in the multi-billion-dollar wellness industry, Toronto-based investment firm Malar Group has announced it has closed the Friends & Family funding round for Attaboy Labs, Inc. The investment is more than just capital; it marks the beginning of a long-term strategic partnership designed to catapult the science-focused supplement brand onto the global stage.

The deal, led by Malar Group founder Sayan Navaratnam, places a powerful bet on Attaboy Labs' "formulation over marketing" philosophy, a stark contrast to the hype-driven landscape of consumer wellness. Attaboy, founded by Nick Lawhon, has gained a loyal following for its flagship product, a daily supplement called 'Every Damn Day,' which consolidates multiple benefits into a single, transparently formulated powder.

A Strategic Bet on Formulation Over Marketing

The partnership is built on a shared conviction that product integrity will ultimately win in a crowded market. Sayan Navaratnam, Founder and CEO of Malar Group, was pointed in his assessment of the industry and his rationale for the investment.

"Most of what we see in the wellness space is marketing in search of a product. Attaboy is the opposite," said Navaratnam. "Clinically-dosed formulations, full ingredient transparency, and a loyal base of customers who actually use the product every day — that's a real business. Nick has built something with genuine conviction behind it, and our job is to help him take it global, starting here at home in Canada."

This philosophy is embodied in 'Every Damn Day.' The supplement distinguishes itself by what it contains and, just as importantly, what it omits. The formula provides a combination of creatine monohydrate (5g), L-citrulline (4g), electrolytes, and cognitive-support ingredients like Alpha-GPC and L-Theanine. Crucially, it contains no caffeine and no "proprietary blends"—a term often used in the industry to obscure the exact amounts of individual ingredients.

By providing ingredients at "clinical doses," Attaboy Labs directly counters the common practice of "fairy-dusting," where trendy ingredients are included in minuscule, ineffective amounts for marketing purposes. For example, the 5-gram dose of creatine aligns with extensive research supporting its benefits for muscle strength and power. Similarly, the inclusion of electrolytes like magnesium glycinate and sodium citrate supports hydration and cognitive function, which can be impacted by even mild dehydration. This commitment to evidence-based formulation and third-party testing for verification provides a level of trust that is increasingly rare and sought after.

The 'Clean Label' Revolution in Wellness

The Malar-Attaboy partnership is not happening in a vacuum. It is a powerful indicator of a broader consumer-led movement often called the "clean label" revolution. Today's consumers are more educated and skeptical than ever, armed with digital tools to scrutinize ingredient lists and question marketing claims. They are demanding transparency, scientific evidence, and products that deliver tangible results.

This trend has given rise to a new class of wellness brands that build their identity on authenticity. They are winning consumer trust by opening up their supply chains, providing third-party testing certificates, and explaining the science behind their formulations in clear, accessible language. Attaboy Labs fits squarely within this vanguard, aiming to simplify complex supplement routines by offering a single, high-efficacy product that replaces multiple pills and powders.

"Their commitment reflects shared conviction that clinically-dosed, transparent wellness products deserve a much bigger stage," said Nick Lawhon, Founder and CEO of Attaboy Labs, Inc. "We're funded, we're focused, and we're ready to scale."

This focus on scaling a product built on substance rather than flash is what attracted Malar Group. The investment firm's portfolio strategy emphasizes backing founder-led, high-conviction brands that are poised to define their categories. By investing in Attaboy, Malar is not just acquiring a stake in a company; it is endorsing a new paradigm for the wellness industry.

An Unconventional Partnership for Global Ambitions

Perhaps the most telling detail of the deal is its structure. Malar Group, a sophisticated institutional investor, participated in what was designated as a "Friends & Family" round. This type of early-stage funding is typically reserved for a founder's personal network and is based more on trust than on rigorous due diligence.

For an institutional firm to lead such a round is highly unusual and signals an exceptionally high level of conviction in Attaboy's founder, product, and market potential. It suggests that Malar Group wanted to secure a foundational role in the company's growth trajectory from the earliest possible moment, likely securing favorable terms in exchange for its early and deeply strategic commitment.

This move provides Attaboy Labs with more than just capital. It offers immediate validation in the eyes of future investors, potential partners, and customers. It also grants the young company access to Malar Group's extensive network and deep expertise in scaling consumer brands, a critical asset for its ambitious expansion plans. The funds will be used to expand its product roadmap, ramp up customer acquisition, and prepare for its first major international push.

Navigating the Path to International Markets

The first stop on Attaboy Labs' global tour is Canada. The strategic partnership with the Toronto-based Malar Group provides a significant home-field advantage for this crucial step. However, entering the Canadian market is not without its challenges.

Health Canada regulates supplements as Natural Health Products (NHPs), requiring a rigorous licensing process. Every product must obtain a Natural Product Number (NPN) by submitting detailed evidence to support its ingredients, dosages, and health claims. Furthermore, any facility that imports, manufactures, or labels the products must hold a site license and adhere to Good Manufacturing Practices (GMP).

While this regulatory hurdle can be daunting, Attaboy Labs' core principles may prove to be its greatest asset. The company's existing commitment to clinically-dosed ingredients, scientific backing, and third-party testing aligns perfectly with the data-driven requirements of Health Canada. This foundation of transparency and quality control could streamline the approval process and build immediate trust with discerning Canadian consumers, who increasingly prioritize safety and efficacy in their wellness choices. The successful navigation of this process will serve as a blueprint for the brand's broader international expansion to follow.